Araujo Leonardo Silva de, Mello Fernanda Carvalho de Queiroz, Silva Nidai de Bárbara Moreira da, Leung Janaina Aparecida Medeiros, Machado Silvia Maria Almeida, Sardella Isabela Gama, Maciel Renata de Moraes, Saad Maria Helena Féres
Laboratory of Cellular Microbiology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil.
Clin Vaccine Immunol. 2014 Apr;21(4):552-60. doi: 10.1128/CVI.00726-13. Epub 2014 Feb 12.
The PstS1 antigen is highly immunogenic, principally when combined with CFP10 during both latent and active TB infection. In the present study, a selected pstS1 gene fragment was cloned, fused with CFP10, and expressed in Escherichia coli. The product [PstS-1(285-374):CFP10] was compared to the recombinant fused RD1 (region of deletion 1) protein (ESAT-6:CFP10) in detecting Mycobacterium tuberculosis infection in 108 recent contacts of pulmonary tuberculosis (TB) cases, considering a positive tuberculin skin test (TST) to be the baseline. The release of gamma interferon (IFN-γ) in 22-h whole-blood and 5-day lymphocyte stimulation assays primed with each antigen was determined. All contacts were clinically followed for up to 1 year, and 87% of the tuberculin skin test-positive (TST(positive)) patients accepted preventative treatment. Concerning the IFN-γ response to PstS-1(285-374):CFP10 in the 22-h and 5-day assays, a slight increase in contact-TST(positive) detection was observed (23/54 and 26/54) compared to the level seen with the RD1 protein (18/54 and 24/54) whereas in the TST(negative) group, similarly lower numbers (≤5/48) of responders were achieved for both antigens, except for RD1 in the 5-day assay (8/48). By combining the IFN-γ responders to both antigens in the 5-day assays, slightly higher increases in positivity were found in the TST(positive) (32/54) and TST(negative) (10/48) groups. Two of 12 untreated TST(positive) contacts progressed to active TB and were concordantly positive in all assays, except for one contact who lacked positivity in the RD1 5-day assay. We demonstrated for the first time that PstS-1(285-374):CFP10 slightly increased contact positivity and detection of active disease progression, suggesting its potential application as a TB infection marker.
PstS1抗原具有高度免疫原性,主要是在潜伏性和活动性结核病感染期间与CFP10结合时。在本研究中,克隆了一个选定的pstS1基因片段,与CFP10融合,并在大肠杆菌中表达。将产物[PstS-1(285 - 374):CFP10]与重组融合RD1(缺失区域1)蛋白(ESAT-6:CFP10)在108例肺结核(TB)病例的近期接触者中检测结核分枝杆菌感染情况进行比较,以结核菌素皮肤试验(TST)阳性作为基线。测定了用每种抗原激发的22小时全血和5天淋巴细胞刺激试验中γ干扰素(IFN-γ)的释放情况。所有接触者均进行了长达1年的临床随访,87%的结核菌素皮肤试验阳性(TST(阳性))患者接受了预防性治疗。关于在22小时和5天试验中对PstS-1(285 - 374):CFP10的IFN-γ反应,与RD1蛋白(18/54和24/54)相比,接触者TST(阳性)检测略有增加(23/54和26/54),而在TST(阴性)组中,两种抗原的反应者数量同样较低(≤5/48),5天试验中的RD1除外(8/48)。通过在5天试验中将两种抗原的IFN-γ反应者合并,在TST(阳性)(32/54)和TST(阴性)(10/48)组中发现阳性率略有更高的增加。12例未经治疗的TST(阳性)接触者中有2例进展为活动性结核病,并且在所有试验中均呈阳性,除了1例接触者在RD1 5天试验中呈阴性。我们首次证明PstS-1(285 - 374):CFP10略微增加了接触者的阳性率并检测到活动性疾病进展,表明其作为结核病感染标志物的潜在应用价值。